Dariimaa Ganbat

Dr. Dariimaa Ganbat

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YTYoshihisa Takahashi
Yoshihisa Takahashi
Erdenetsogt DungubatErdenetsogt Dungubat
Erdenetsogt Dungubat
HKHiroyuki Kusano
Hiroyuki Kusano
DGDariimaa Ganbat
Dariimaa Ganbat
YTYasuhiko Tomita
Yasuhiko Tomita
TFToshio Fukusato
Toshio Fukusato
Although radiological diagnostics have been progressing, pathological diagnosis remains the most reliable method for diagnosing liver tumors. In some cases, definite pathological diagnosis cannot be obtained by histological evaluation alone, especially when the sample is a small biopsy; in such cases, immunohistochemical staining is very useful. Immunohistochemistry is the most frequently used technique for molecular pathological diagnosis due to its broad application, ease of performance and evaluation, and reasonable cost. The results occasionally reflect specific genetic mutations. The immunohistochemical markers of hepatocellular carcinoma include those of hepatocellular differentiation—such as hepatocyte paraffin 1 and arginase-1—and those of malignant hepatocytes—such as glypican-3, heat shock protein 70, and glutamine synthetase (GS). To classify the subtypes of hepatocellular adenoma, examination of several immunohistochemical markers, such as liver fatty acid-binding protein, GS, and serum amyloid A, is indispensable. Immunohistochemical staining for GS is also important for the diagnosis of focal nodular hyperplasia. The representative immunohistochemical markers of intrahepatic cholangiocarcinoma include cytokeratin (CK) 7 and CK19. In this article, we provide an overview of the application of immunohistochemistry in the pathological diagnosis of liver tumors referring to the association with genetic alterations. Furthermore, we aimed to explain the practical points in the differential diagnosis of liver tumors by immunohistochemical staining.

3 May 2024 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
GGGantsetseg Garmaa
Gantsetseg Garmaa
SBStefania Bunduc
Stefania Bunduc
TKTamás Kói
Tamás Kói
Peter HegyiPeter Hegyi
Peter Hegyi
Dezső CsuporDezső Csupor
Dezső Csupor
Gábor KökényGábor Kökény
Gábor Kökény
Chronic kidney disease (CKD) represents an increasing health burden. Evidence suggests the importance of miRNA in diagnosing CKD, yet the reports are inconsistent. This study aimed to determine novel miRNA biomarkers and potential therapeutic targets from hypothesis-free miRNA profiling studies in human and murine CKDs. Comprehensive literature searches were conducted on five databases. Subgroup analyses of kidney diseases, sample types, disease stages, and species were conducted. A total of 38 human and 12 murine eligible studies were analyzed using Robust Rank Aggregation (RRA) and vote-counting analyses. Gene set enrichment analyses of miRNA signatures in each kidney disease were conducted using DIANA-miRPath v4.0 and MIENTURNET. As a result, top target genes, Gene Ontology terms, the interaction network between miRNA and target genes, and molecular pathways in each kidney disease were identified. According to vote-counting analysis, 145 miRNAs were dysregulated in human kidney diseases, and 32 were dysregulated in murine CKD models. By RRA, miR-26a-5p was significantly reduced in the kidney tissue of Lupus nephritis (LN), while miR-107 was decreased in LN patients’ blood samples. In both species, epithelial-mesenchymal transition, Notch, mTOR signaling, apoptosis, G2/M checkpoint, and hypoxia were the most enriched pathways. These miRNA signatures and their target genes must be validated in large patient cohort studies.

1 July 2021 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
DGDariimaa Ganbat
Dariimaa Ganbat
BJBat-Erdene Jugder
Bat-Erdene Jugder
LGLkhamaa Ganbat
Lkhamaa Ganbat
MTMiki Tomoeda
Miki Tomoeda
Erdenetsogt DungubatErdenetsogt Dungubat
Erdenetsogt Dungubat
YTYasuhiko Tomita
Yasuhiko Tomita
Background: Redox dysregulation originating from metabolic alterations in cancer cells contributes to their proliferation, invasion, and resistance to therapy. Conversely, these features represent a specific vulnerability of malignant cells that can be selectively targeted by redox chemotherapeutics. Amongst them, Vitamin K (VitK) carries the potential against cancer stem cells, in addition to the rest of tumor mass. Objectives: To assess the possible benefits and safety of VitK for cancer treatment using a systematic review and meta-analysis with a mixed-methods approach. Methods: We performed a systematic search on several electronic databases for studies comparing VitK treatment with and without combination to the control groups. For quantitative studies, fully or partially reported clinical outcomes such as recurrence rates, survival, overall response and adverse reactions were assessed. For qualitative studies, a narrative synthesis was accomplished. Results: Our analysis suggested that the clinical outcome of efficacy, the pooled hazard ratio for progression-free survival, and the pooled relative risk for overall survival, and overall response were significantly higher in the VitK therapy group compared to the placebo group (p<0.05). We did not observe any significant difference in the occurrence of adverse events between groups. Among qualitative studies, VitK treatment targeting myelodysplastic syndrome and advanced solid tumors resulted in 24.1% and 10% of clinical response, respectively. Conclusion: VitK not only exerts antitumor effects against a wide range of tumor types, but it also has excellent synergism with other therapeutic agents.


20 August 2026 in Addictive Behaviors Reports
Verified
Journal Article
Open access
BNBilguun Nyamdorj
Bilguun Nyamdorj
KDKhongorzul Davaadorj
Khongorzul Davaadorj
TKTergel Khuyag
Tergel Khuyag
UMUranchimeg Mungunkhuyag
Uranchimeg Mungunkhuyag
MMMunkhnaran Mandakh
Munkhnaran Mandakh
ODOyunsuren Davaasuren
Oyunsuren Davaasuren
Evidence on drug-related problem severity and injection-related harm among people using psychoactive substances in Mongolia is limited, particularly in institutional settings. We examined DAST-28 scores, internal consistency, and behavioral correlates in psychiatric and correctional settings. This multicenter cross-sectional study included 181 participants recruited from the National Center for Mental Health and correctional facilities. The continuous DAST-28 total score was the primary outcome. Internal consistency was evaluated from 28 item responses. A clinically specified seven-covariate linear model with HC3 heteroskedasticity-robust standard errors was primary; ordinal and study-defined DAST-28 ≥ 12 models were supportive analyses. DAST-28 scores were available for 179 participants (median 11.0, interquartile range 6.0-16.0). Among 170 participants with complete item responses, Cronbach's alpha was 0.882 (95% bootstrap confidence interval 0.854-0.902). In the primary model, correctional setting was associated with a 1.82-point lower score (95% CI -3.36 to -0.28), whereas each additional year of use (B = 0.27, 95% CI 0.08-0.45), polysubstance use (B = 2.64, 95% CI 0.79-4.50), and any syringe use (B = 4.43, 95% CI 2.58-6.28) were associated with higher scores. Ordinal and threshold analyses were concordant; variance inflation factors ranged from 1.05 to 1.59. Greater DAST-28 scores were associated with polysubstance use, syringe use, and longer use duration in these institutional samples. The findings may inform comprehensive assessment and harm-reduction linkage but do not establish a diagnostic cutoff, causal relationship, intervention effectiveness, or population prevalence.

19 September 2026 in Cureus
Verified
Journal Article
Open access
PDF file
JHJin Ai Hua
Jin Ai Hua
BSBa Hu Shan
Ba Hu Shan
TNTa Na
Ta Na
WMWu Da Mu
Wu Da Mu
DQDeng Yu Qi
Deng Yu Qi
DGDariimaa Ganbat
Dariimaa Ganbat
Traditional bonesetting (TBS) remains an important source of fracture care in many low- and middle-income settings. Still, its evidence base is difficult to interpret because care pathways are heterogeneous, practitioner-dependent, and often incompletely specified. This methodological review synthesizes recurring design and reporting problems in TBS research and translates established complex-intervention principles into a practical framework. PubMed was the principal biomedical source, supplemented by Google Scholar, citation chaining, and targeted searches of methodological and implementation literature; the literature update extended through August 31, 2026. Major threats to interpretation include exposure misclassification, poorly described provider expertise and comparators, confounding by indication, absent pretreatment outcomes, inconsistent follow-up, passive harm ascertainment, and limited fidelity assessment. Recent observational evidence linking specific immobilization and topical practices to serious outcomes, along with training and collaborative-care studies, reinforces the need to evaluate components and care pathways rather than the TBS label alone. We propose the TBS-8 Framework: intervention specification; provider characterization, training, and expertise; comparator definition; baseline prognostic measurement; allocation and confounding control; outcome and follow-up architecture; active safety surveillance; and process evaluation. Randomized and pragmatic designs are appropriate only when genuine clinical equipoise exists and randomization is ethical and feasible; prospective comparative cohorts can be informative when preference, access, or safety considerations limit randomization. The TBS-8 Framework is conceptual and unvalidated. Its purpose is to translate established methodological principles and recurrent TBS-specific problems into eight proposed core domains for reproducible, measurable, and safety-conscious comparative-effectiveness and implementation research.